Sells it 53%, $38.9B a quarter“Pharmacy Benefit Services revenue growth reflected claims composition, while income was pressured by client-focused initiatives, partly offset by Specialty and Care Services growth and operating efficiencies.”
Latest 10-QQ3 FY2026MixedRestructuring ·
Rebate-free investment and contract renewals squeeze Evernorth’s pharmacy-benefit earnings; specialty care provides an offset.
Revenue$73.7BYoY +5.6%
Net income$1.4BYoY −22.8%
Latest 8-KEarningsGuidance raised ·
Pharmacy Benefit Services renewals and investments squeezed income; FY2026 adjusted EPS outlook raised to at least $30.60
Latest 8-KLeadership change ·
Donna F. Zarcone will retire from Cigna’s board effective Dec. 31, 2026.
Sells it“Other exposures include PBM legislation affecting rebates, reporting and Medicare Part D compensation; No Surprises Act disputes; mental-health-parity requirements; litigation and government reviews; cyber, privacy, technology and data-integrity risks; competition; and potential goodwill or intangible-asset impairment.”
Latest 10-QQ3 FY2026Mixed ·
Carelon’s specialty pharmacy and care-services gains fell short of offsetting medical-cost pressure in Health Benefits.
Revenue$51.4BYoY +1.4%
Net income$1.4BYoY +14.8%
Latest 8-KGuidance reaffirmed ·
FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.
Latest 8-KPositiveEarningsGuidance raised ·
Carelon growth contrasts with Health Benefits weakness; FY2026 adjusted EPS outlook raised to ≥$29